This trial utilized Abituzumab in combination with luteinizing hormone antagonist/agonist treatment every three weeks in patients with confirmed bone lesions in resistant castration-metastatic prostate cancer .
This trial utilized Abituzumab in combination with luteinizing hormone antagonist/agonist treatment every three weeks in patients with confirmed bone lesions in metastatic castration-resistant prostate cancer .